Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy? [Yahoo! Finance]
Travere Therapeutics, Inc. (TVTX)
Company Research
Source: Yahoo! Finance
The position represents 1.99% of 13F assets under management (AUM). Travere Therapeutics is not among the fund's top five holdings after the trade. These 10 stocks could mint the next wave of millionaires › According to a Securities and Exchange Commission (SEC) filing dated January 20, 2026, Palisades Investment Partners, LLC reported initiating a new position in Travere Therapeutics (NASDAQ:TVTX) The fund acquired 137,768 shares, with the estimated value of the trade at $5.26 million based on the quarterly average share price. The new stake's quarter-end value also totaled $5.26 million, reflecting the company's share price at period close. This new position accounts for 1.99% of Palisades Investment Partners' $264.72 million in reportable U.S. equity assets as of December 31, 2025 Top five holdings after the filing: NASDAQ: STRL: $29.86 million (11.3% of AUM) NYSE: SPXC: $23.04 million (8.7% of AUM) NASDAQ: WGS: $11.34 million (4.3% of AUM) NASDAQ: KRYS: $10.54
Show less
Read more
Impact Snapshot
Event Time:
TVTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TVTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TVTX alerts
High impacting Travere Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TVTX
News
- Travere Therapeutics (NASDAQ:TVTX) had its "neutral" rating reaffirmed by analysts at Piper Sandler.MarketBeat
- Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit [Yahoo! Finance]Yahoo! Finance
- Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech SummitBusiness Wire
- Is Travere Therapeutics (TVTX) Facing a Credibility Test in Its Disclosure and Risk Narrative? [Yahoo! Finance]Yahoo! Finance
- TVTX ALERT: Investigation Launched into Travere Therapeutics, Inc., Robbins Geller Rudman & Dowd LLP Encourages Investors and Potential Witnesses to Contact Law FirmGlobeNewswire
TVTX
Earnings
- 10/30/25 - Beat
TVTX
Sec Filings
- 2/9/26 - Form SCHEDULE
- 2/5/26 - Form 4
- 2/5/26 - Form 4
- TVTX's page on the SEC website